TACE联合恩替卡韦治疗乙型肝炎相关的原发性肝癌的疗效分析

Clinical Efficacy of TACE Combined with Entecavir for Hepatitis B Related Primary Liver Cancer

目的探讨TACE联合恩替卡韦治疗乙型肝炎相关的原发性肝癌的疗效。方法按照入院顺序抽签后随机将97例原发性肝癌患者分为实验组和对照组,对照组给予TACE治疗,实验组给予TACE联合恩替卡韦治疗,对比2组近期和远期疗效。结果实验组治疗后ALT、HBV DNA水平均明显低于治疗前和对照组,有统计学差异(P<0.05);对照组治疗前后,ALT、HBV DNA水平变化,无统计学差异(P>0.05)。实验组HBe Ag转阴率和转换率明显高于对照组,差异有统计学意义(P<0.05)。实验组治疗后ORR、DCR明显高于对照组(P<0.05);实验组患者中位总生存时间(OS)和中位无进展生存时间(PFS)均明显高于对照组,有统计学差异(P<0.05)。结论 TACE联合恩替卡韦治疗乙型肝炎相关的原发性肝癌效果较好,患者ALT、HBV DNA水平改善较好,HBe Ag转阴率和转换率较高,ORR、DCR较高,患者中位总生存时间和中位无进展生存时间均较高,临床应用价值较高。

Objective To explore the clinical efficacy of TACE combined with entecavir for hepatitis b related primary liver cancer. Methods 97 cases of patients with primary liver cancer were randomly divided into the experiment group and the control group, the control group were treated by TACE, the experiment group were treated by TACE combine with entecavir. Short- term and long-term clinical efficacy of the 2 groups were compared. Results The levels of ALT, HBV DNA in the experiment group after treatment were lower than before treatment and the control group（ P 〈 0.05 ） ;There had no significant difference in the levels of ALT, HBV DNA in the control group（ P 〉 0.05 ） ;The HBeAg negative conversion ratio and inversion in the experiment group were higher than the control group（ P 〈 0.05 ） ;The ORR, DCR in the experiment group were higher than the control group （ P 〈 0.05 ） ; The OS and PFS in the experiment group were higher than the control group （ P 〈 0.05 ）. Conclusion It has good clinical effects for the patients with hepatitis b related primary liver cancer by TACE combine with entecavir, it can improve the levels of ALT, HBV DNA, with high rate of HBeAg negative conversion ratio and inversion, it has high ORR, DCR, median overall survival time and median progression-free survival time, it has high value of clinical application.